Please login to the form below

Not currently logged in
Email:
Password:

Executive leak continues at AZ as another head jumps ship

James Ward-Lilley will become CEO of lung drug specialist Vectura

AZ London HQ 

Just weeks after AstraZeneca lost its research chief a second senior executive has left the company to become the head of a small biotech firm.

James Ward-Lilley has left the Anglo-Swedish company to become the new chief executive at Vectura, a biotech that specialises in lung drug treatments.

Ward-Lilley had been heading up AZ's respiratory and inflammatory business - a core unit for the firm.

This also comes just two weeks after its former chief medical officer Briggs Morrison also jumped ship from the world's eight largest pharma firm, also to head up a small biotech. 

An AstraZeneca spokesperson has said the timing of the departures was "pure coincidence" and both men were moving on to new and different types of challenges as business leaders. 

Vectura said Ward-Lilley would become CEO from October this year and replaces Chris Blackwell, whose departure had already been announced and who will leave the small drug company at the end of June. 

AZ's future was in doubt last year when rival pharma firm Pfizer tried to force a $118bn acquisition of the company, only to be rejected in May. AZ has since gone on to forge an independent strategy.

Article by
Ben Adams

25th June 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...